Hazard regression model and cure rate model in colon cancer relative survival trends: are they telling the same story?
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Hazard regression models and cure rate models can be advantageously used in cancer relative survival analysis. We explored the advantages and limits of these two models in colon cancer and focused on the prognostic impact of the year of diagnosis on survival according to the TNM stage at diagnosis. The analysis concerned 9,998 patients from three French registries. In the hazard regression model, the baseline excess death hazard and the time-dependent effects of covariates were modelled using regression splines. The cure rate model estimated the proportion of ‘cured’ patients and the excess death hazard in ‘non-cured’ patients. The effects of year of diagnosis on these parameters were estimated for each TNM cancer stage. With the hazard regression model, the excess death hazard decreased significantly with more recent years of diagnoses (hazard ratio, HR 0.97 in stage III and 0.98 in stage IV, P < 0.001). In these advanced stages, this favourable effect was limited to the first years of follow-up. With the cure rate model, recent years of diagnoses were significantly associated with longer survivals in ‘non-cured’ patients with advanced stages (HR 0.95 in stage III and 0.97 in stage IV, P < 0.001) but had no significant effect on cure (odds ratio, OR 0.99 in stages III and IV, P > 0.5). The two models were complementary and concordant in estimating colon cancer survival and the effects of covariates. They provided two different points of view of the same phenomenon: recent years of diagnosis had a favourable effect on survival, but not on cure.
- Remontet L, Esteve J, Bouvier AM, et al. Cancer incidence and mortality in France over the period 1978–2000. Rev Epidemiol Sante Publique 2003;51:3–30.
- Finn-Faivre C, Maurel J, Benhamiche AM, et al. Evidence of improving survival of patients with rectal cancer in France: a population-based study. Gut 1999;44:377–81. CrossRef
- Faivre-Finn C, Bouvier-Benhamiche AM, Phelip JM, Manfredi S, Dancourt V, Faivre J. Colon cancer in France: evidence for improvement in management and survival. Gut 2002;51:60–4. CrossRef
- Mitry E, Bouvier AM, Esteve J, Faivre J. Improvement in colorectal cancer survival: a population-based study. Eur J Cancer 2005;41:2297–303. CrossRef
- Bossard N, Velten M, Remontet L, Belot A, Maarouf N, Bouvier AM, et al. Survival of cancer patients in France: a population-based study from The Association of the French Cancer Registries (FRANCIM). Eur J Cancer 2007;43(1):149–60. CrossRef
- Blomqvist P, Ekbom A, Nyren O, Krusemo U, Bergström R, Adami HO. Survival after colon cancer 1973–1990 in Sweden. Convergence between catchment areas. Ann Surg 1997;225:208–16. CrossRef
- Verdecchia A, De Andelis R, Capocaccia R, et al. The cure for colon cancer: results from the Eurocare study. Int J Cancer 1998;77:322–9. CrossRef
- Sant M, Capocaccia R, Coleman M, et al. Cancer survival increases in Europe, but international differences remain wide. Eur J Cancer 2001;37:1659–67. CrossRef
- Ries LA, Wingo PA, Miller DS, et al. The annual report to the nation on the status of cancer, 1973–1997, with a special section on colorectal cancer. Cancer 2000;88:2398–424. CrossRef
- Ederer F, Axtell LM, Cutler SJ. The relative survival rate: a statistical methodology. Natl Cancer Inst Monogr 1961;6:101–21.
- Hakulinen T. Cancer survival corrected for heterogeneity in patient withdrawal. Biometrics 1982;38:933–42. CrossRef
- Esteve J, Benhamou E, Croasdale M, Raymond L. Relative survival and the estimation of the net survival: elements for further discussion. Stat Med 1990;9:528–38. CrossRef
- Hakulinen T, Tenkanen L. Regression analysis of relative survival rates. Appl Stat 1987;36:309–17. CrossRef
- Remontet L, Bossard N, Belot A, Estève J. An overall strategy based on regression models to estimate relative survival and model the effects of prognostic factors in cancer survival studies. Stat Med 2007;26:2214–28. CrossRef
- Boag JW. Maximum likelihood estimates of the proportion of patients cured by cancer therapy. J Roy Stat Soc B 1949;11:15–44.
- Berkson J, Gage RP. Survival curves for cancer patients following treatment. J Am Stat Assoc 1952;47:501–15. CrossRef
- Farewell VT. The use of mixture models for the analysis of survival data with long-term survivors. Biometrics 1982;38:1041–6. CrossRef
- De Angelis R, Capocaccia R, Hakulinen T, Soderman B, Verdecchia A. Mixture models for cancer survival analysis: application to population-based data with covariates. Stat Med 1999;18:441–54. CrossRef
- Sposto R. Cure model analysis in cancer: an application to data from the Children’s cancer group. Stat Med 2002;21:293–312. CrossRef
- World Health Organisation. International statistical classification of diseases and related health problems, tenth revision. Geneva: World Health Organisation 1992.
- TNM classification of malignant tumours. 5th ed. New York: Wiley Inc.; 1997.
- Gatta G, Capocaccia R, Sant M, et al. Understanding variations in survival for colorectal cancer in Europe: a EUROCARE high resolution study. Gut 2000;47:533–8. CrossRef
- Bolard P, Quantin C, Abrahamowicz M, et al. Assessing time-by-covariate interactions in relative survival models using restrictive cubic spline functions. J Cancer Epidemiol Prev 2002;7:113–22.
- Giorgi R, Abrahamowicz M, Quantin C, et al. A relative survival regression model using B-splines functions to model non-proportional hazards. Stat Med 2003;22:2767–84. CrossRef
- Abrahamowicz M, MacKenzie T, Esdaile JM. Time-dependent hazard ratio: modelling and hypothesis testing with application in Lupus Nephritis. J Am Stat Assoc 1996;91:1432–9. CrossRef
- Roncucci L, Fante R, Losi L, et al. Survival for colon and rectal cancer in a population-based cancer registry. Eur J Cancer 1996;32:295–302. CrossRef
- Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;322:352–8. CrossRef
- Faivre-Finn C, Bouvier AM, Mitry E, Rassiat E, Clinard F, Faivre J. Chemotherapy for colon cancer in a well-defined French population: is it under- or over-prescribed? Aliment Pharmacol Ther 2002;16:353–9. CrossRef
- Hazard regression model and cure rate model in colon cancer relative survival trends: are they telling the same story?
European Journal of Epidemiology
Volume 23, Issue 4 , pp 251-259
- Cover Date
- Print ISSN
- Online ISSN
- Springer Netherlands
- Additional Links
- Cure rate model
- Hazard regression model
- Relative survival (RS)
- Time-dependent effect
- Industry Sectors
- Author Affiliations
- 1. Hospices Civils de Lyon, Service de Biostatistiques, Centre Hospitalier Lyon Sud, 69495, Pierre-Bénite, France
- 2. CNRS, UMR 5558 Equipe Biostatistique-Santé, Villeurbanne, 69100, France
- 3. Université Lyon 1, UMR 5558 Laboratoire Biostatistique-Santé, Villeurbanne, 69100, France
- 4. Registre des cancers digestifs, INSERM EMI 0106, Dijon, France
- 5. Université de Bourgogne, Dijon, France
- 6. CHU de Dijon, Dijon, France
- 7. Département des Maladies Chroniques et des Traumatismes, Institut de Veille Sanitaire, Saint-Maurice, France
- 10. CHU Caen, Caen, France
- 8. INSERM ERI3 ‘Cancers & Populations’, Caen, France
- 9. EA 3936 Université Caen, UF Epidémiologie—Pôle de Santé des Populations, Caen, France